Showing results (291-300 of 315) with videos related to
Sort By:
Pageof 32
Scientific Reports|June 21, 2018
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic ratsPhilipp Schwabl, Ksenia Brusilovskaya, Paul Supper, et al.Proceedings of the National Academy of Sciences of the United States of America|February 2, 2026
Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancersSalomon Tendler, Roberto De Gregorio, Paul Balderes, et al.Cell Reports Methods|September 6, 2023
Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2Vilja Pietiäinen, Minttu Polso, Ede Migh, et al.Nature Communications|November 5, 2025
Spatial single-cell atlas reveals regional variations in healthy and diseased human lungAlexandra B Firsova, Sergio Marco Salas, Louis B Kuemmerle, et al.Journal of Medicinal Chemistry|February 21, 2015
Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitorsEmily A Peterson, Yohannes Teffera, Brian K Albrecht, et al.BMC Infectious Diseases|May 16, 2023
Risk factors for SARS-CoV-2 seropositivity in a health care worker population during the early pandemicSebastian D Schubl, Cesar Figueroa, Anton M Palma, et al.Journal of Medicinal Chemistry|January 27, 2016
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor ActivityAlessandro A Boezio, Katrina W Copeland, Karen Rex, et al.Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitorsAlessandro A Boezio, Loren Berry, Brian K Albrecht, et al.Elife|July 29, 2021
Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strainsNikhil Faulkner, Kevin W Ng, Mary Y Wu, et al.Journal of Hepatology|December 6, 2021
HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver diseaseGeorg Semmler, Elias Laurin Meyer, Karin Kozbial, et al.Pageof 32